A phase 1b open‐label study of sodium selenate as a disease‐modifying treatment for possible behavioral variant frontotemporal dementia

Abstract Introduction Sodium selenate increases tau dephosphorylation through protein phosphatase 2 activation. Here we report an open‐label Phase 1b study of sodium selenate as a disease‐modifying treatment for behavioral variant frontotemporal dementia (bvFTD). Methods Twelve participants with bvF...

Descripció completa

Dades bibliogràfiques

Autors principals:	Lucy Vivash, Charles B. Malpas, Christian Meletis, Meghan Gollant, Dhamidhu Eratne, Qiao‐Xin Li, Stuart McDonald, William T. O'Brien, Amy Brodtmann, David Darby, Christopher Kyndt, Mark Walterfang, Christopher M. Hovens, Dennis Velakoulis, Terence J. O'Brien
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2022-01-01
Col·lecció:	Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Matèries:	anti‐tau treatment behavioral variant frontotemporal dementia (bvFTD) clinical trial fluid biomarkers frontotemporal lobar degeneration (FTLD) magnetic resonance imaging (MRI)
Accés en línia:	https://doi.org/10.1002/trc2.12299
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!